- Home
- CTXR vs SST Comparison
CTXR vs SST Comparison
Compare CTXR & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- SST
- Stock Information
- Founded
- CTXR 2007
- SST 2013
- Country
- CTXR United States
- SST United States
- Employees
- CTXR N/A
- SST N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- SST Diversified Commercial Services
- Sector
- CTXR Health Care
- SST Consumer Discretionary
- Exchange
- CTXR Nasdaq
- SST Nasdaq
- Market Cap
- CTXR 84.9M
- SST 73.0M
- IPO Year
- CTXR N/A
- SST N/A
- Fundamental
- Price
- CTXR $0.20
- SST $0.97
- Analyst Decision
- CTXR Strong Buy
- SST Hold
- Analyst Count
- CTXR 2
- SST 1
- Target Price
- CTXR $5.00
- SST $2.00
- AVG Volume (30 Days)
- CTXR 2.0M
- SST 110.9K
- Earning Date
- CTXR 12-27-2024
- SST 11-07-2024
- Dividend Yield
- CTXR N/A
- SST N/A
- EPS Growth
- CTXR N/A
- SST N/A
- EPS
- CTXR N/A
- SST N/A
- Revenue
- CTXR N/A
- SST $364,450,000.00
- Revenue This Year
- CTXR N/A
- SST N/A
- Revenue Next Year
- CTXR N/A
- SST $15.17
- P/E Ratio
- CTXR N/A
- SST N/A
- Revenue Growth
- CTXR N/A
- SST N/A
- 52 Week Low
- CTXR $0.19
- SST $0.91
- 52 Week High
- CTXR $1.07
- SST $3.02
- Technical
- Relative Strength Index (RSI)
- CTXR 29.06
- SST 40.08
- Support Level
- CTXR $0.31
- SST $1.03
- Resistance Level
- CTXR $0.51
- SST $1.17
- Average True Range (ATR)
- CTXR 0.06
- SST 0.08
- MACD
- CTXR -0.01
- SST 0.00
- Stochastic Oscillator
- CTXR 3.83
- SST 19.96
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.